ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
61 368,23
0,94%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Daxor Corporation (DXR)

  7. Daxor Corporation (DXR) Actualités

DXR Daxor Corporation

9,5527
-0,121 (-1,25%)
10 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Daxor Corporation DXR NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,121 -1,25% 9,5527 22:10:38
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
9,67 9,49 9,67 9,5527 9,6737
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
16/4/202414:00GLOBENew Studies Prove the Clinical Benefits of Daxor’s Blood..
15/4/202414:00GLOBEDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR..
10/4/202414:00GLOBEDaxor Corporation Announces New Hospital Account at Leading..
01/4/202414:00GLOBEDaxor Corporation to Exhibit at the American College of..
25/3/202413:00GLOBEDaxor Corporation Acquires Volumex® and Megatope® From Its..
22/3/202413:00GLOBEDaxor Corporation to Hold Investor Call Discussing Fiscal..
18/3/202419:18GLOBEDaxor Corporation CEO and President Michael Feldschuh..
11/3/202413:00GLOBEDaxor Announces Sales to Three New Hospitals Furthering..
08/3/202419:49EDGAR2Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of..
08/3/202414:00GLOBEMulti-Center Study Presented by Duke at Heart Failure..
06/3/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202423:28EDGAR2Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of..
29/2/202422:15EDGAR2Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of..
26/2/202414:00GLOBEDaxor Corporation to Exhibit at the Technology and Heart..
12/2/202414:00GLOBEDaxor Corporation Starts 2024 with Ongoing Growth in New..
07/2/202414:00GLOBEDaxor Corporation Closes Q4 2023 with Growth in New Sales to..
29/1/202414:00GLOBEDaxor Corporation to Exhibit at the Society of Nuclear..
16/1/202414:00GLOBEDaxor Corporation to Exhibit at the Society for Critical..
09/1/202414:00GLOBEDAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME..
02/1/202414:52EDGAR2Form 8-K - Current report
02/1/202414:30GLOBEDaxor Corporation Submits Dual 510(k)/CLIA-waiver..
06/12/202321:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/12/202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/12/202302:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202312:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202319:53EDGAR2Form NPORT-P - Monthly Portfolio Investments Report on Form..
24/11/202317:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202314:00GLOBENew Randomized Controlled Trial Demonstrates the Efficacy of..
13/11/202312:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202314:00GLOBEDaxor Corporation Awarded New Patent for Remote Monitoring..
02/11/202323:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/10/202323:27EDGAR2Form 8-K - Current report
16/10/202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/10/202314:00GLOBEExpert Panelists Advocate Use of Daxor’s Technology to..
11/10/202314:00GLOBENew Data from Banner University Medicine Demonstrating..
04/10/202314:00GLOBEDaxor Corporation Awarded Support from the National..
27/9/202314:00GLOBEDaxor Corporation to Exhibit at the Heart Failure Society of..
26/9/202315:14EDGAR2Form 40-17G - Fidelity Bond [Rule 17G-1(g)]
26/9/202314:00GLOBEDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR..
20/9/202322:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/9/202318:00GLOBEDaxor Corporation Awarded $305K Grant from the National..
07/9/202315:15GLOBEDaxor Corporation to Present at the H.C. Wainwright 25th..
28/8/202322:15GLOBEDaxor Corporation CEO and President Michael Feldschuh..
28/8/202322:05GLOBEDaxor Corporation Reports a 20.64 Percent Increase in..
28/8/202322:01EDGAR2Form N-CSRS - Certified Shareholder Report, Semi-Annual
15/8/202313:14EDGAR2Form N-PX - Annual Report of proxy voting record of..
10/8/202314:00GLOBEJACC-HF Reports Successful Heart Failure Trial With Daxor..
13/7/202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
DXR
Daxor
HITB
REMETH
Remme
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés